Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors

REFERENCES

• Weiden P, Flournoy N, Thomas E, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. New Engl J Med 1979;300:1068–1073.
   PubMed Web of Science ®Google Scholar
• Sullivan K, Weiden P, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C. Influence of acute and chronic graft versus host disease on relapse and survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720–1728.
   PubMed Web of Science ®Google Scholar
• Dadmarz R, Sgagias N, Rosenberg S, Schwartzentruber DJ. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC class II restricted fashion. Cancer Immunol Immunother 1995;40:1–9.
   PubMed Web of Science ®Google Scholar
• Odom L, August C, Githens J, Humbert JR, Morse H, Peakman D, Sharma B, Rusnak SL, Johnson FB. Remission of relapsed leukemia during a graft versus host reaction. Lancet 1978;2: 537–540.
   PubMed Web of Science ®Google Scholar
• Drobyski W, Keever C, Roth M, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: effficacy and toxicity of a defined T cell dose. Blood 1993;82:2310–2318.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Conradt C, Legha S, Khayat D, Scheibenbogen C, Thatcher N, Goey S, Gore M, Darval T, Hancock B, Punt CJ, Dummer R, Avril MF, Bröcker EB, Benhammouda A, Eggermont AM, Pritsch M. Results of interleukin-2 based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921–2929.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose IL-2. JAMA 1994;271:907– 913.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. J Immunol 1981;126:1318–1322.
   PubMed Web of Science ®Google Scholar
• Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984;159:495–450.
   PubMed Web of Science ®Google Scholar
• Liu KY, Chen YH, Liu DH, Xu LP, Huang XJ. A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. Bone Marrow Transplant 2008;42(8):535–539.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Koh LP, Long GD, Gasparetto C, Vredenburgh JJ, Smith C, Buckley PH, Stenzel T, Gong G, Lagoo A, Davis P, Rooney B, Niedzwiecki D, Waters-Pick B, Burleson J, Thompson M, Davis P, Rowe K, Folz R, Chao NJ. Clinical outcome and immune reconstitution following Alemtuzumab T cell depleted mismatched non-myeloablative allogoneic immunotherapy. J Clin Oncol 2007;25:690–697.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Storms R, Chen D, Long GD, Nikcevich DA, Gasparetto C, Horwitz M, Chute J, Sullivan K, Hennig T, Misra D, Apple C, Baker M, Morris A, Green PG, Hasselblad V, Chao NJ. Natural killer cell enriched donor lymphocyte infusions from A 3–6/6 HlA matched family member following non-myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Trans 2010;16:1107–1114.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, Volin L, Gurman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol 2007;25:4938–4945.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Chao NJ. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3–6/6 HLA matched donors. Bone Marrow Transplant 2009;43:327–333.
   PubMed Web of Science ®Google Scholar
• Higuchi C, Thompson J, Petersen F, Buckner C, Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991;77:2561–2568.
   PubMed Web of Science ®Google Scholar
• Heslop H, Gottlieb D, Bianchi A, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989;74:1374–1380.
   PubMed Web of Science ®Google Scholar
• Rosenberg S, Yang J, Schwarzentruber D, Hwu R, Marincola F, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968–975.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008;111:4048–4054.
   PubMed Web of Science ®Google Scholar
• Meehan K, Wu J, Bengtson E, Hill J, Ely P, Szczepiorkowski Z, Kendall M, Ernstoff MS. Early recovery of aggressive cytotoxic cells and improved immune resurgence post-transplant immunotherapy for multiple myeloma. BMT 2007;39:695–703.
   Google Scholar
• Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS. IL2 based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. BMT 2003;32: 177–186.
   Google Scholar
• Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body radiation, etoposide, cyclophosphamide, and autologouis peripheral blood stem cell transplanttion followed by randomization to therapy with interleukin –2 versus observation for patients with NHL: results of a phase 3 randomized trial by the SWOG. Blood 2008;111:4048–4054.
   PubMed Web of Science ®Google Scholar
• Ballester O, Fang T, Raptis A, Ballester G, Wilcox P, Hiemenz J, Tan B. Adoptive immunotherapy with DLIs and IL2 after high dose therapy and autologous stem cell rescue for multiple myeloma. BMT 2004;34:419–423.
   Google Scholar
• Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica 2008;93:1852–1858.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribiero RC, Pounds S, Rooney B, Teresa B, Pui CH, Leung W. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplanation in childhood acute myeloid leukemia. J Clin Oncol 2010;28:955–959.
   PubMed Web of Science ®Google Scholar
• Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571– 1579.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Murray C, Cochran K, Ritz J. Clinical and immunologic effects of prolonged infusion of low dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992;79:517– 526.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell depleted allogeneic bone marrow transplantation. Blood 1994;84:964–971.
   PubMed Web of Science ®Google Scholar